alendronate has been researched along with Pain in 42 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta." | 9.12 | Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. ( Arlot, M; Charrin, JE; Chevrel, G; Duboeuf, F; Fontanges, E; Garnero, P; Lina-Granade, G; Meunier, PJ; Raynal, C; Schott, AM, 2006) |
| "To evaluate the effects of the antiresorptive agent alendronate at a daily oral dose of 40 mg in patients with posttraumatic complex regional pain syndrome type I (CRPS I) of the lower extremity." | 9.11 | Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. ( Boutsen, Y; Brasseur, JP; Depreseux, G; Devogelaer, JP; Manicourt, DH, 2004) |
| " In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis." | 7.72 | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004) |
| "This trial will give helpful and high-quality evidence regarding the potential therapeutic role of alendronate sodium vitamin D3, as compared to placebo, in the management of patients with knee OA regarding its role on cartilage loss, radiographic progression of OA, severity of OA, knee pain, quality of life, and inflammatory biomarkers." | 5.51 | Effect of alendronate sodium plus vitamin D ( Cai, DZ; Feng, B; Li, Y; Peng, HM; Qian, W; Wan, S; Weng, XS; Yang, Y; Yao, ZJ; Zhang, C; Zhao, C, 2022) |
| "Chronic back pain is one of the most important complications of postmenopausal osteoporosis." | 5.46 | Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis. ( Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H, 2017) |
| "Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy." | 5.14 | Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). ( Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N, 2010) |
| "A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta." | 5.12 | Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. ( Arlot, M; Charrin, JE; Chevrel, G; Duboeuf, F; Fontanges, E; Garnero, P; Lina-Granade, G; Meunier, PJ; Raynal, C; Schott, AM, 2006) |
| "To evaluate the effects of the antiresorptive agent alendronate at a daily oral dose of 40 mg in patients with posttraumatic complex regional pain syndrome type I (CRPS I) of the lower extremity." | 5.11 | Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. ( Boutsen, Y; Brasseur, JP; Depreseux, G; Devogelaer, JP; Manicourt, DH, 2004) |
| "The present study was planned to assess the safety, tolerability and efficacy on bone mineral density (BMD), pain, quality of life and fracture risk of alendronate, calcitonin and calcium treatments." | 5.09 | Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. ( Dursun, E; Dursun, N; Yalçin, S, 2001) |
| " Other end points included changes in urinary deoxypyridinoline excretion, pain, functional impairment scores, and radiological osteolysis." | 5.08 | Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. ( Altman, R; Conte, JM; Favus, M; Lombardi, A; Lyles, K; McIlwain, H; Murphy, WA; Reda, C; Rude, R; Seton, M; Siris, E; Thompson, D; Tiegs, R; Tucci, JR; Weinstein, RS; Yates, AJ; Zimering, M, 1996) |
| "Alendronate reduces pain, improves function and retards AVN progression." | 3.73 | Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. ( Agarwala, S; Jain, D; Joshi, VR; Sule, A, 2005) |
| " In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis." | 3.72 | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004) |
| "Alendronate treatment by standard dose for osteoporosis showed clinical efficacy for decreasing pain but failed to show preventive effects for structural progression of hip osteoarthritis." | 2.78 | Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. ( Nishii, T; Shiomi, T; Sugano, N; Tamura, S; Yoshikawa, H, 2013) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| "The degree of pain is highly variable and adults reports more pain than children." | 2.48 | Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. ( Chapurlat, RD; Gensburger, D; Ghilardi, JR; Jimenez-Andrade, JM; Kelly, M; Mantyh, P, 2012) |
| "After a 2-week treatment, pain-related behavior was examined using von Frey filaments." | 1.56 | Functional Block of Interleukin-6 Reduces a Bone Pain Marker but Not Bone Loss in Hindlimb-Unloaded Mice. ( Kato, S; Miyamura, G; Nagao, N; Naito, Y; Sudo, A; Wakabayashi, H, 2020) |
| "Ovariectomy induced bone loss and mechanical hyperalgesia in the hindlimbs with upregulation of CGRP expression in the DRG neurons innervating the hindlimbs." | 1.51 | Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis. ( Kato, S; Miyamura, G; Nagao, N; Naito, Y; Sudo, A; Wakabayashi, H, 2019) |
| "Chronic back pain is one of the most important complications of postmenopausal osteoporosis." | 1.46 | Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis. ( Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H, 2017) |
| "Alendronate caused an increase in the pain threshold value and inhibited c-Fos expression." | 1.42 | Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice. ( Abe, Y; Amizuka, N; Chiba, H; Iba, K; Kanaya, K; Kawamata, T; Oda, K; Sasaki, K; Sasaki, M; Yamashita, T, 2015) |
| "Patients with a diagnosis of postmenopausal osteoporosis, bisphosphonate usage of at least 5 years and prodromal pain prior to fracture were included the study." | 1.39 | Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy. ( Çakmak, S; Erdik, B; Keklikçi, K; Mahiroğulları, M; Rodop, O; Sarı, E, 2013) |
| "Subtrochanteric insufficiency fractures in post-menopausal patients have not been commonly reported in the literature." | 1.35 | An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? ( Goh, SK; Howe, TS; Koh, JS; Kwek, EB; Png, MA, 2008) |
| " We believe that this finding is important and indicates the need for caution in the long-term use of alendronate in the treatment of osteoporosis." | 1.34 | Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. ( Chua, DT; Chua, SY; Goh, SK; Howe, TS; Koh, JS; Wong, MK; Yang, KY, 2007) |
| "Alendronate use was also associated with a reduction in knee pain according to the WOMAC scores." | 1.32 | The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. ( Barrow, KD; Carbone, LD; Felson, D; Harris, F; Harris, TB; Kritchevsky, SB; Nevitt, MC; Peterfy, C; Visser, M; Wang, BW; Wildy, K, 2004) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 5 (11.90) | 18.2507 |
| 2000's | 22 (52.38) | 29.6817 |
| 2010's | 11 (26.19) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, HM | 1 |
| Weng, XS | 1 |
| Li, Y | 1 |
| Feng, B | 1 |
| Qian, W | 1 |
| Cai, DZ | 1 |
| Zhao, C | 1 |
| Yao, ZJ | 1 |
| Yang, Y | 1 |
| Zhang, C | 1 |
| Wan, S | 1 |
| Wakabayashi, H | 5 |
| Miyamura, G | 4 |
| Nagao, N | 3 |
| Kato, S | 5 |
| Naito, Y | 6 |
| Sudo, A | 5 |
| Nakagawa, T | 3 |
| Iino, T | 2 |
| Çakmak, S | 1 |
| Mahiroğulları, M | 1 |
| Keklikçi, K | 1 |
| Sarı, E | 1 |
| Erdik, B | 1 |
| Rodop, O | 1 |
| Nishii, T | 1 |
| Tamura, S | 1 |
| Shiomi, T | 1 |
| Yoshikawa, H | 1 |
| Sugano, N | 1 |
| Abe, Y | 1 |
| Iba, K | 2 |
| Sasaki, K | 1 |
| Chiba, H | 1 |
| Kanaya, K | 1 |
| Kawamata, T | 1 |
| Oda, K | 1 |
| Amizuka, N | 1 |
| Sasaki, M | 1 |
| Yamashita, T | 2 |
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Amin, NL | 1 |
| James, RM | 1 |
| Phillips, R | 1 |
| Chao, K | 1 |
| Katznelson, L | 1 |
| Kotecha, RS | 1 |
| Powers, N | 1 |
| Lee, SJ | 1 |
| Murray, KJ | 1 |
| Carter, T | 1 |
| Cole, C | 1 |
| Ward, LM | 1 |
| Rauch, F | 1 |
| Whyte, MP | 1 |
| D'Astous, J | 1 |
| Gates, PE | 1 |
| Grogan, D | 1 |
| Lester, EL | 1 |
| McCall, RE | 1 |
| Pressly, TA | 1 |
| Sanders, JO | 1 |
| Smith, PA | 1 |
| Steiner, RD | 1 |
| Sullivan, E | 1 |
| Tyerman, G | 1 |
| Smith-Wright, DL | 1 |
| Verbruggen, N | 1 |
| Heyden, N | 1 |
| Lombardi, A | 2 |
| Glorieux, FH | 1 |
| Chapurlat, RD | 1 |
| Gensburger, D | 1 |
| Jimenez-Andrade, JM | 1 |
| Ghilardi, JR | 2 |
| Kelly, M | 1 |
| Mantyh, P | 1 |
| Ogata, A | 1 |
| Kitano, M | 1 |
| Hashimoto, N | 1 |
| Iwasaki, T | 1 |
| Hamano, T | 1 |
| Kakishita, E | 1 |
| Minne, HW | 2 |
| Pollähne, W | 1 |
| Pfeifer, M | 2 |
| Begerow, B | 2 |
| Hinz, C | 1 |
| Maffei, L | 1 |
| Murata, Y | 1 |
| Rochira, V | 1 |
| Tubert, G | 1 |
| Aranda, C | 1 |
| Vazquez, M | 1 |
| Clyne, CD | 1 |
| Davis, S | 1 |
| Simpson, ER | 1 |
| Carani, C | 1 |
| Walsh, JP | 1 |
| Ward, LC | 1 |
| Stewart, GO | 1 |
| Will, RK | 1 |
| Criddle, RA | 1 |
| Prince, RL | 1 |
| Stuckey, BG | 1 |
| Dhaliwal, SS | 1 |
| Bhagat, CI | 1 |
| Retallack, RW | 1 |
| Kent, GN | 1 |
| Drury, PJ | 1 |
| Vasikaran, S | 1 |
| Gutteridge, DH | 1 |
| Chun, CS | 1 |
| Gerster, JH | 1 |
| Sevcik, MA | 1 |
| Luger, NM | 1 |
| Mach, DB | 1 |
| Sabino, MA | 1 |
| Peters, CM | 1 |
| Schwei, MJ | 1 |
| Röhrich, H | 1 |
| De Felipe, C | 1 |
| Kuskowski, MA | 1 |
| Mantyh, PW | 1 |
| Carbone, LD | 1 |
| Nevitt, MC | 1 |
| Wildy, K | 1 |
| Barrow, KD | 1 |
| Harris, F | 1 |
| Felson, D | 1 |
| Peterfy, C | 1 |
| Visser, M | 1 |
| Harris, TB | 1 |
| Wang, BW | 1 |
| Kritchevsky, SB | 1 |
| Manicourt, DH | 1 |
| Brasseur, JP | 1 |
| Boutsen, Y | 1 |
| Depreseux, G | 1 |
| Devogelaer, JP | 1 |
| Agarwala, S | 2 |
| Jain, D | 1 |
| Joshi, VR | 2 |
| Sule, A | 2 |
| Wysowski, DK | 1 |
| Chang, JT | 1 |
| Kaplan, RJ | 1 |
| Vo, AN | 1 |
| Stitik, TP | 1 |
| Kamen, LB | 1 |
| Bitar, AA | 1 |
| Shih, VC | 1 |
| Chevrel, G | 1 |
| Schott, AM | 1 |
| Fontanges, E | 1 |
| Charrin, JE | 1 |
| Lina-Granade, G | 1 |
| Duboeuf, F | 1 |
| Garnero, P | 1 |
| Arlot, M | 1 |
| Raynal, C | 1 |
| Meunier, PJ | 1 |
| Hartman, JM | 1 |
| Berger, A | 1 |
| Baker, K | 1 |
| Bolle, J | 1 |
| Handel, D | 1 |
| Mannes, A | 1 |
| Pereira, D | 1 |
| St Germain, D | 1 |
| Ronsaville, D | 1 |
| Sonbolian, N | 1 |
| Torvik, S | 1 |
| Calis, KA | 1 |
| Phillips, TM | 1 |
| Cizza, G | 1 |
| Goh, SK | 2 |
| Yang, KY | 1 |
| Koh, JS | 2 |
| Wong, MK | 1 |
| Chua, SY | 1 |
| Chua, DT | 1 |
| Howe, TS | 2 |
| Takada, J | 1 |
| Kamasaki, H | 1 |
| Oda, T | 1 |
| Hatakeyama, N | 1 |
| Wada, T | 1 |
| Kwek, EB | 1 |
| Png, MA | 1 |
| Siris, E | 1 |
| Weinstein, RS | 1 |
| Altman, R | 1 |
| Conte, JM | 1 |
| Favus, M | 1 |
| Lyles, K | 1 |
| McIlwain, H | 1 |
| Murphy, WA | 1 |
| Reda, C | 1 |
| Rude, R | 1 |
| Seton, M | 1 |
| Tiegs, R | 1 |
| Thompson, D | 1 |
| Tucci, JR | 1 |
| Yates, AJ | 1 |
| Zimering, M | 1 |
| Body, JJ | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Adami, S | 1 |
| Goicoechea, C | 1 |
| Porras, E | 1 |
| Alfaro, MJ | 1 |
| Martín, MI | 1 |
| Oura, S | 1 |
| Sakurai, T | 1 |
| Yoshimura, G | 1 |
| Tamaki, T | 1 |
| Umemura, T | 1 |
| Kokawa, Y | 1 |
| Dursun, N | 1 |
| Dursun, E | 1 |
| Yalçin, S | 1 |
| Pai, BU | 1 |
| Passeri, M | 1 |
| Baroni, MC | 1 |
| Pedrazzoni, M | 1 |
| Pioli, G | 1 |
| Barbagallo, M | 1 |
| Costi, D | 1 |
| Biondi, M | 1 |
| Girasole, G | 1 |
| Arlunno, B | 1 |
| Palummeri, E | 1 |
| Attardo-Parrinello, G | 1 |
| Merlini, G | 1 |
| Pavesi, F | 1 |
| Crema, F | 1 |
| Fiorentini, ML | 1 |
| Ascari, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Alendronate Sodium Vitamin D3 Tablets on Knee Joint Structure and Knee Osteoarthritis Pain: A Multi-center, Randomized, Double-blind, Controlled Study.[NCT04739592] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-07-07 | Recruiting | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for alendronate and Pain
| Article | Year |
|---|---|
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe | 2016 |
Pathophysiology and medical treatment of pain in fibrous dysplasia of bone.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Neoplasms; Fibrous Dysplasia of | 2012 |
[Rehabilitation in osteoporosis].
Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain | 2003 |
Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Chron | 2004 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C | 1997 |
12 trials available for alendronate and Pain
| Article | Year |
|---|---|
Effect of alendronate sodium plus vitamin D
Topics: Alendronate; Cholecalciferol; Double-Blind Method; Humans; Knee Joint; Multicenter Studies as Topic; | 2022 |
Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Bone | 2013 |
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chem | 2010 |
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Topics: Adolescent; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Child; Chil | 2011 |
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Calcium; | 2004 |
Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity.
Topics: Administration, Oral; Adult; Alendronate; Collagen; Collagen Type I; Double-Blind Method; Drug Admin | 2004 |
Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Biomarkers; Bone Density; Bone Den | 2006 |
Quality of life and pain in premenopausal women with major depressive disorder: the POWER Study.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin Gene-Related Peptide; | 2006 |
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids | 1996 |
Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
Topics: Alendronate; Analysis of Variance; Bone Density; Calcitonin; Calcium; Female; Follow-Up Studies; Hum | 2001 |
Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Female; Humans; Middle Aged; Osteop | 1991 |
Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Bone Ne | 1987 |
23 other studies available for alendronate and Pain
| Article | Year |
|---|---|
Functional Block of Interleukin-6 Reduces a Bone Pain Marker but Not Bone Loss in Hindlimb-Unloaded Mice.
Topics: Alendronate; Animals; Behavior, Animal; Biomarkers; Bone and Bones; Bone Resorption; Ganglia, Spinal | 2020 |
Prevention of bone loss and improvement of pain-related behavior in hind limb-unloaded mice by administration of teriparatide and bisphosphonate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hindli | 2021 |
The effects of bisphosphonate on pain-related behavior and immunohistochemical analyses in hindlimb-unloaded mice.
Topics: Alendronate; Animals; Behavior, Animal; Bone Density Conservation Agents; Disease Models, Animal; Hi | 2018 |
Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis.
Topics: Alendronate; Animals; Antibodies; Behavior, Animal; Bone Density Conservation Agents; Combined Modal | 2019 |
Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Early Diagn | 2013 |
Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice.
Topics: Acid Phosphatase; Alendronate; Animals; Diphosphonates; Disease Models, Animal; Female; Isoenzymes; | 2015 |
Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis.
Topics: Alendronate; Animals; Biomarkers; Bone Density Conservation Agents; Calcitonin Gene-Related Peptide; | 2017 |
Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull.
Topics: Administration, Oral; Adult; Alendronate; Bone Density Conservation Agents; Dose-Response Relationsh | 2008 |
Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
Topics: Adult; Alendronate; Biomarkers; Bone Diseases; Drug Therapy, Combination; Female; Humans; Multiple M | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
Topics: Acanthosis Nigricans; Adult; Alendronate; Aromatase; Arteriosclerosis; Bone and Bones; Cryptorchidis | 2004 |
Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis.
Topics: Acute Disease; Alendronate; Arthralgia; Arthritis; Drug Administration Schedule; Female; Humans; Joi | 2004 |
Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis.
Topics: Activating Transcription Factor 3; Alendronate; Animals; Behavior, Animal; Biomarkers, Tumor; Bone N | 2004 |
The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis.
Topics: Aged; Alendronate; Arthrography; Bone Resorption; Case-Control Studies; Cross-Sectional Studies; Est | 2004 |
Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study.
Topics: Adolescent; Adult; Aged; Alendronate; Bone Resorption; Disability Evaluation; Female; Femur Head Nec | 2005 |
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone and Bones; Child; Etidroni | 2005 |
Rehabilitation of orthopedic and rheumatologic disorders. 1. Osteoporosis assessment, treatment, and rehabilitation.
Topics: Alendronate; Analgesics, Opioid; Cyclooxygenase Inhibitors; Diagnosis, Differential; Humans; Osteopo | 2005 |
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; F | 2007 |
A significant improvement in lower limb pain after treatment with alendronate in two cases of Camurati-Engelmann disease.
Topics: Adolescent; Adult; Alendronate; Camurati-Engelmann Syndrome; Child; Female; Femur; Humans; Male; Pai | 2008 |
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femora | 2008 |
Alendronate induces antinociception in mice, not related with its effects in bone.
Topics: Acetic Acid; Alendronate; Analgesics; Animals; Bone Density; Dose-Response Relationship, Drug; Forma | 1999 |
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Ne | 2000 |
Alendronate in the treatment of avascular necrosis of the hip.
Topics: Adult; Alendronate; Disability Evaluation; Female; Femur Head Necrosis; Gait; Hip Joint; Humans; Mal | 2002 |